Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Retained Earnings: 2009-2024

Historic Retained Earnings for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -$24.0 million.

  • Cumberland Pharmaceuticals' Retained Earnings fell 15.08% to -$25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.4 million, marking a year-over-year decrease of 15.08%. This contributed to the annual value of -$24.0 million for FY2024, which is 37.05% down from last year.
  • Cumberland Pharmaceuticals' Retained Earnings amounted to -$24.0 million in FY2024, which was down 37.05% from -$17.5 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Retained Earnings peaked at -$2.1 million during FY2020, and registered a low of -$24.0 million during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$17.5 million (2023), whereas its average is -$17.6 million.
  • Data for Cumberland Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 276.35% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Retained Earnings stood at -$2.1 million in 2020, then plummeted by 164.60% to -$5.6 million in 2021, then plummeted by 98.79% to -$11.2 million in 2022, then plummeted by 56.02% to -$17.5 million in 2023, then tumbled by 37.05% to -$24.0 million in 2024.